IMMUNE CHECKPOINT INHIBITORS (ICIS)
Clinical trials for IMMUNE CHECKPOINT INHIBITORS (ICIS) explained in plain language.
Never miss a new study
Get alerted when new IMMUNE CHECKPOINT INHIBITORS (ICIS) trials appear
Sign up with your email to follow new studies for IMMUNE CHECKPOINT INHIBITORS (ICIS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for lung cancer: smart drug combo targets hidden DNA signals
Disease control Recruiting nowThis study tests whether adding a new drug (ivonescimab) to standard chemotherapy can help people with advanced non-small cell lung cancer who had a good long-term response to initial immunotherapy but still have cancer DNA in their blood. About 70 participants will be randomly a…
Matched conditions: IMMUNE CHECKPOINT INHIBITORS (ICIS)
Phase: PHASE2 • Sponsor: Second Xiangya Hospital of Central South University • Aim: Disease control
Last updated May 17, 2026 00:59 UTC
-
New study aims to predict dangerous blood clots in lung cancer patients on immunotherapy
Knowledge-focused Recruiting nowThis observational study tracks 2,400 lung cancer patients treated with immune checkpoint inhibitors to understand how often blood clots (in veins or arteries) occur and what raises that risk. Researchers will compare patients who develop clots with those who don't, looking for b…
Matched conditions: IMMUNE CHECKPOINT INHIBITORS (ICIS)
Sponsor: Beijing Chao Yang Hospital • Aim: Knowledge-focused
Last updated May 14, 2026 12:03 UTC